Clinical Trial Update: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma [Phase 3]

View source ↗

Summary

An ongoing Phase 3 clinical trial is evaluating TLX101-Tx plus standard of care vs standard of care alone in patients with recurrent glioblastoma; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• TLX101-Tx

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Neoplastic Disease, Glioblastoma | Phase 3 | Status: RECRUITING